



National Coverage Determination (NCD) Update

Benefit: Autologous treatment for cancer with chimeric antigen receptor T-cells

Effective Date: August 7, 2019

On August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) announced its determination regarding:

1. The coverage for autologous treatment with T-cells for cancer, which have at least one chimeric antigen receptor (CAR) when:
 - a. It is administered in a healthcare facility enrolled in the Food and Drug Administration's (FDA's) Risk Evaluation and Mitigation Strategies (REMS) program.
 - b. It is used for medically accepted indications, as defined in the Social Security Act, Section 1861 (t) (2).
 - c. It is used for other indications with an FDA-approved product whose use has been recognized by CMS-approved compendiums.

2. Maintaining coverage for routine study costs when chimeric antigen receptor therapy is used as an investigative agent in a clinical trial in accordance with the requirements in the national coverage determination established for this purpose.

To access the memo containing the CMS decision, go to: <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=291&bc=AAAAAAAAACAA&>.



MCS Classicare is a product subscribed by MCS Advantage, Inc. MCS Advantage, Inc. cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo. MCS Advantage, Inc. complies with federal civil rights laws applicable and does not discriminate on grounds of race, color, national origin, age, disability or sex. MCS Advantage, Inc. 遵守適用的聯邦民權法律規定，不因種族、膚色、民族血統、年齡、殘障或性別而歧視任何人。 ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llama al 1.866.627.8183 (TTY: 1.866.627.8182). ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1.866.627.8183 (TTY: 1.866.627.8182).注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電